GlassScriptPhysician profile
Christine G Simone
NPI 1649591660
$36,995.14
in general payments reported to CMS, 2019-2025
99 companies · $4,455 in 2025
The $4,455 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $2,835 · 2021: $3,513 · 2022: $3,911 · 2023: $4,162 · 2024: $4,379 · 2025: $4,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,504.76 |
| Education | $490.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11,999.37 | 2019-2025 | |
| Janssen Biotech, INC. | $2,303.98 | 2019-2025 | Erleada, Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals LP | $2,172.33 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $1,412.23 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Amgen INC. | $1,128.24 | 2019-2023 | Nplate, Xgeva, Kyprolis |
| Glaxosmithkline, LLC. | $1,123.02 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Merck Sharp & Dohme LLC | $1,121.02 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $1,119.62 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Celgene Corporation | $1,114.95 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Astellas Pharma US INC | $1,086.36 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Genentech USA, INC. | $893.02 | 2019-2025 | Tecentriq, Venclexta, Itovebi |
| Novartis Pharmaceuticals Corporation | $787.46 | 2019-2025 | |
| Incyte Corporation | $661.39 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $639.32 | 2019-2025 | |
| Seagen INC. | $555.28 | 2019-2023 | Tukysa, Adcetris, Tivdak |
Show all 99 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Simone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.